Dr. Kris on the EML4-ALK Translocation in Lung Cancer

Mark G. Kris, MD
Published: Friday, Mar 25, 2011

Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).

Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x